Cadrenal Therapeutics公司公布二期数据:CAD-1005实现血栓事件绝对风险降低超25%

美股速递
Apr 30

Cadrenal Therapeutics公司最新发布的二期临床试验数据显示,其核心候选药物CAD-1005在降低血栓事件发生率方面展现出突破性疗效。研究结果表明,与对照组相比,CAD-1005治疗组患者的血栓事件发生风险实现了超过25%的绝对降幅。

这一显著疗效数据为CAD-1005的后续临床开发奠定了坚实基础。血栓性疾病作为全球范围内的主要健康威胁,新型治疗方案的突破备受医疗界关注。CAD-1005所展现的优异数据,不仅验证了其作用机制的有效性,更为患者带来了新的治疗希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10